<?xml version='1.0' encoding='utf-8'?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2011//EN" "http://www.ncbi.nlm.nih.gov/entrez/query/DTD/pubmed_110101.dtd">
<pubmedarticleset>
 <pubmedarticle>
  <medlinecitation owner="NLM" status="MEDLINE">
   <pmid version="1">
    16539718
   </pmid>
   <datecreated>
    <year>
     2006
    </year>
    <month>
     04
    </month>
    <day>
     10
    </day>
   </datecreated>
   <datecompleted>
    <year>
     2006
    </year>
    <month>
     04
    </month>
    <day>
     25
    </day>
   </datecompleted>
   <daterevised>
    <year>
     2009
    </year>
    <month>
     11
    </month>
    <day>
     18
    </day>
   </daterevised>
   <article pubmodel="Electronic">
    <journal>
     <issn issntype="Electronic">
      1471-2334
     </issn>
     <journalissue citedmedium="Internet">
      <volume>
       6
      </volume>
      <pubdate>
       <year>
        2006
       </year>
      </pubdate>
     </journalissue>
     <title>
      BMC infectious diseases
     </title>
     <isoabbreviation>
      BMC Infect. Dis.
     </isoabbreviation>
    </journal>
    <articletitle>
     Feasibility, acceptability, and cost of tuberculosis testing by whole-blood interferon-gamma assay.
    </articletitle>
    <pagination>
     <medlinepgn>
      47
     </medlinepgn>
    </pagination>
    <abstract>
     <abstracttext label="BACKGROUND" nlmcategory="BACKGROUND">
      The whole-blood interferon-gamma release assay (IGRA) is recommended in some settings as an alternative to the tuberculin skin test (TST). Outcomes from field implementation of the IGRA for routine tuberculosis (TB) testing have not been reported. We evaluated feasibility, acceptability, and costs after 1.5 years of IGRA use in San Francisco under routine program conditions.
     </abstracttext>
     <abstracttext label="METHODS" nlmcategory="METHODS">
      Patients seen at six community clinics serving homeless, immigrant, or injection-drug user (IDU) populations were routinely offered IGRA (Quantiferon-TB). Per guidelines, we excluded patients who were &lt;17 years old, HIV-infected, immunocompromised, or pregnant. We reviewed medical records for IGRA results and completion of medical evaluation for TB, and at two clinics reviewed TB screening logs for instances of IGRA refusal or phlebotomy failure.
     </abstracttext>
     <abstracttext label="RESULTS" nlmcategory="RESULTS">
      Between November 1, 2003 and February 28, 2005, 4143 persons were evaluated by IGRA. 225(5%) specimens were not tested, and 89 (2%) were IGRA-indeterminate. Positive or negative IGRA results were available for 3829 (92%). Of 819 patients with positive IGRA results, 524 (64%) completed diagnostic evaluation within 30 days of their IGRA test date. Among 503 patients eligible for IGRA testing at two clinics, phlebotomy was refused by 33 (7%) and failed in 40 (8%). Including phlebotomy, laboratory, and personnel costs, IGRA use cost $33.67 per patient tested.
     </abstracttext>
     <abstracttext label="CONCLUSION" nlmcategory="CONCLUSIONS">
      IGRA implementation in a routine TB control program setting was feasible and acceptable among homeless, IDU, and immigrant patients in San Francisco, with results more frequently available than the historically described performance of TST. Laboratory-based diagnosis and surveillance for M. tuberculosis infection is now possible.
     </abstracttext>
    </abstract>
    <affiliation>
     Division of Tuberculosis Elimination, Centers for Disease Control and Prevention, Atlanta, Georgia, USA. phd8@cdc.gov
    </affiliation>
    <authorlist completeyn="Y">
     <author validyn="Y">
      <lastname>
       Dewan
      </lastname>
      <forename>
       Puneet Kumar
      </forename>
      <initials>
       PK
      </initials>
     </author>
     <author validyn="Y">
      <lastname>
       Grinsdale
      </lastname>
      <forename>
       Jennifer
      </forename>
      <initials>
       J
      </initials>
     </author>
     <author validyn="Y">
      <lastname>
       Liska
      </lastname>
      <forename>
       Sally
      </forename>
      <initials>
       S
      </initials>
     </author>
     <author validyn="Y">
      <lastname>
       Wong
      </lastname>
      <forename>
       Ernest
      </forename>
      <initials>
       E
      </initials>
     </author>
     <author validyn="Y">
      <lastname>
       Fallstad
      </lastname>
      <forename>
       Robert
      </forename>
      <initials>
       R
      </initials>
     </author>
     <author validyn="Y">
      <lastname>
       Kawamura
      </lastname>
      <forename>
       L Masae
      </forename>
      <initials>
       LM
      </initials>
     </author>
    </authorlist>
    <language>
     eng
    </language>
    <publicationtypelist>
     <publicationtype>
      Journal Article
     </publicationtype>
    </publicationtypelist>
    <articledate datetype="Electronic">
     <year>
      2006
     </year>
     <month>
      03
     </month>
     <day>
      15
     </day>
    </articledate>
   </article>
   <medlinejournalinfo>
    <country>
     England
    </country>
    <medlineta>
     BMC Infect Dis
    </medlineta>
    <nlmuniqueid>
     100968551
    </nlmuniqueid>
    <issnlinking>
     1471-2334
    </issnlinking>
   </medlinejournalinfo>
   <chemicallist>
    <chemical>
     <registrynumber>
      82115-62-6
     </registrynumber>
     <nameofsubstance>
      Interferon-gamma
     </nameofsubstance>
    </chemical>
   </chemicallist>
   <citationsubset>
    IM
   </citationsubset>
   <commentscorrectionslist>
    <commentscorrections reftype="Cites">
     <refsource>
      Am J Respir Crit Care Med. 2000 Apr;161(4 Pt 1):1376-95
     </refsource>
     <pmid version="1">
      10764337
     </pmid>
    </commentscorrections>
    <commentscorrections reftype="Cites">
     <refsource>
      Am J Respir Crit Care Med. 2000 Apr;161(4 Pt 2):S221-47
     </refsource>
     <pmid version="1">
      10764341
     </pmid>
    </commentscorrections>
    <commentscorrections reftype="Cites">
     <refsource>
      JAMA. 2001 Oct 10;286(14):1740-7
     </refsource>
     <pmid version="1">
      11594899
     </pmid>
    </commentscorrections>
    <commentscorrections reftype="Cites">
     <refsource>
      J Urban Health. 2002 Mar;79(1):113-27
     </refsource>
     <pmid version="1">
      11937620
     </pmid>
    </commentscorrections>
    <commentscorrections reftype="Cites">
     <refsource>
      MMWR Recomm Rep. 2003 Jan 31;52(RR-2):15-8
     </refsource>
     <pmid version="1">
      12583541
     </pmid>
    </commentscorrections>
    <commentscorrections reftype="Cites">
     <refsource>
      Am J Infect Control. 2003 Oct;31(6):347-53
     </refsource>
     <pmid version="1">
      14608301
     </pmid>
    </commentscorrections>
    <commentscorrections reftype="Cites">
     <refsource>
      Am J Respir Crit Care Med. 1999 Jan;159(1):295-300
     </refsource>
     <pmid version="1">
      9872853
     </pmid>
    </commentscorrections>
    <commentscorrections reftype="Cites">
     <refsource>
      Lancet Infect Dis. 2004 Dec;4(12):761-76
     </refsource>
     <pmid version="1">
      15567126
     </pmid>
    </commentscorrections>
    <commentscorrections reftype="Cites">
     <refsource>
      Tuberculosis (Edinb). 2005 May;85(3):137-45
     </refsource>
     <pmid version="1">
      15850752
     </pmid>
    </commentscorrections>
    <commentscorrections reftype="Cites">
     <refsource>
      Am J Respir Crit Care Med. 2005 Sep 1;172(5):631-5
     </refsource>
     <pmid version="1">
      15961696
     </pmid>
    </commentscorrections>
    <commentscorrections reftype="Cites">
     <refsource>
      Clin Infect Dis. 1993 Dec;17(6):968-75
     </refsource>
     <pmid version="1">
      8110954
     </pmid>
    </commentscorrections>
    <commentscorrections reftype="Cites">
     <refsource>
      Am J Public Health. 1998 May;88(5):792-6
     </refsource>
     <pmid version="1">
      9585747
     </pmid>
    </commentscorrections>
    <commentscorrections reftype="Cites">
     <refsource>
      Clin Diagn Lab Immunol. 2004 Nov;11(6):1089-93
     </refsource>
     <pmid version="1">
      15539511
     </pmid>
    </commentscorrections>
   </commentscorrectionslist>
   <meshheadinglist>
    <meshheading>
     <descriptorname majortopicyn="N">
      Adolescent
     </descriptorname>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Adult
     </descriptorname>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Aged
     </descriptorname>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Aged, 80 and over
     </descriptorname>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Child
     </descriptorname>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Child, Preschool
     </descriptorname>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Cohort Studies
     </descriptorname>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Feasibility Studies
     </descriptorname>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Health Care Costs
     </descriptorname>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Humans
     </descriptorname>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Immunoassay
     </descriptorname>
     <qualifiername majortopicyn="N">
      methods
     </qualifiername>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Interferon-gamma
     </descriptorname>
     <qualifiername majortopicyn="Y">
      blood
     </qualifiername>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Mass Screening
     </descriptorname>
     <qualifiername majortopicyn="Y">
      economics
     </qualifiername>
     <qualifiername majortopicyn="Y">
      methods
     </qualifiername>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Middle Aged
     </descriptorname>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Patient Acceptance of Health Care
     </descriptorname>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Risk Factors
     </descriptorname>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Time Factors
     </descriptorname>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Tuberculosis
     </descriptorname>
     <qualifiername majortopicyn="Y">
      diagnosis
     </qualifiername>
    </meshheading>
   </meshheadinglist>
   <otherid source="NLM">
    PMC1434750
   </otherid>
  </medlinecitation>
  <pubmeddata>
   <history>
    <pubmedpubdate pubstatus="received">
     <year>
      2005
     </year>
     <month>
      11
     </month>
     <day>
      16
     </day>
    </pubmedpubdate>
    <pubmedpubdate pubstatus="accepted">
     <year>
      2006
     </year>
     <month>
      3
     </month>
     <day>
      15
     </day>
    </pubmedpubdate>
    <pubmedpubdate pubstatus="aheadofprint">
     <year>
      2006
     </year>
     <month>
      3
     </month>
     <day>
      15
     </day>
    </pubmedpubdate>
    <pubmedpubdate pubstatus="pubmed">
     <year>
      2006
     </year>
     <month>
      3
     </month>
     <day>
      17
     </day>
     <hour>
      9
     </hour>
     <minute>
      0
     </minute>
    </pubmedpubdate>
    <pubmedpubdate pubstatus="medline">
     <year>
      2006
     </year>
     <month>
      4
     </month>
     <day>
      28
     </day>
     <hour>
      9
     </hour>
     <minute>
      0
     </minute>
    </pubmedpubdate>
    <pubmedpubdate pubstatus="entrez">
     <year>
      2006
     </year>
     <month>
      3
     </month>
     <day>
      17
     </day>
     <hour>
      9
     </hour>
     <minute>
      0
     </minute>
    </pubmedpubdate>
   </history>
   <publicationstatus>
    epublish
   </publicationstatus>
   <articleidlist>
    <articleid idtype="pii">
     1471-2334-6-47
    </articleid>
    <articleid idtype="doi">
     10.1186/1471-2334-6-47
    </articleid>
    <articleid idtype="pubmed">
     16539718
    </articleid>
    <articleid idtype="pmc">
     PMC1434750
    </articleid>
   </articleidlist>
  </pubmeddata>
 </pubmedarticle>
</pubmedarticleset>

